Bio-Techne Stock Forecast
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TECH analyst consensus
Consensus (13 analysts)
hold
Avg. price target
$70.50-2.80%
- Strong buy 0
- Buy 1
- Hold 12
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Bio-Techne (2026-10-07), 1 rate the stock a buy or strong buy, 12 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $70.50, with a high estimate of $73.00 and a low estimate of $50.00. The average target implies downside of 2.8% from the current price of $72.53.
The spread between the highest and lowest targets is 46.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TECH.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 8% |
| Hold | 12 | 92% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $50.00 | -31.06% |
| Average target | $70.50 | -2.80% |
| High target | $73.00 | +0.65% |